Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck's total revenue grew by +13% CER[1] (+10% DKK) to DKK 16,463 milli ...

Begin your TipRanks Premium journey today. Longboard Pharmaceuticals (LBPH) Company Description: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ...

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its ...

ETCO Inc. has introduced a full range of battery and ignition terminals, extension cord components and other connector types that are manufactured in the USA for ...

Longboard Pharmaceuticals, Inc. ( (LBPH) ) has released its Q3 earnings. Here is a breakdown of the information Longboard Pharmaceuticals, Inc.

SEC filing, will be determined "based on the book-building process" — but Medicus said it is expected to be close to the ...

On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a decline, ending the day at $59.5 which represents a decrease of $-0.19 or -0.32% from the prior close of $59.69. The stock opened at $59.66 ...

On Friday, Longboard Pharmaceuticals Inc (LBPH) stock saw a decline, ending the day at $59.69 which represents a decrease of $-0.03 or -0.05% from the prior close of $59.72. The stock opened at $59.95 ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) have earned an average rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...